I am honored to release this interview with Bobby Ardila, V.P. of International Medical Communications for Neo Matrix, LLC. Neo Matrix is a newly formed cell therapy company serving the U.S.A. and South American markets. In this interview, we explore the company’s use of a placental tissue matrix component for regenerative medicine applications.
Reversing Type I Diabetes with Encapsulated Cell Therapy Technology
This is an interview with Gary Harlem, CEO of Altucell, a company exploring novel cell therapy approaches to treating Type I diabetes. In addition to diabetes, the company’s core encapsulation technology is applicable to a wide range of autoimmune and chronic degenerative disorders.
While Altucell is an American company, it has secured intellectual property rights on encapsulation patents from a team of researchers at the University of Perugia, Italy, led by Dr. Riccardo Calafiore, M.D. [Read more…]
Sistemic and Cynata to Collaborate on an In-process Purity Assay for Cynata’s iPSC-Derived Mesenchymal Stem Cells
Based in Glasgow, UK, Sistemic Ltd. is a company that specializes in microRNA-based services and kit-based products. Cynata Therapeutics is a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP).
Cynata’s Cymerus™ technology utilizes iPSCs originating from an adult donor as the starting material for generating mesenchymal stem cells (MSCs). The importance of this technology is that it is a process for manufacturing a consistent cell therapy product.
Cynata’s lead product is CYP-oo1, an iPSC-derived mesenchymal stem cell product that is anticipated to be the world’s first allogeneic iPSC product to enter a clinical trial.
Cynata’s lead product is CYP-oo1, an iPSC-derived mesenchymal stem cell product that is anticipated to be the In the press release below, Sistemic Ltd. and Cynata Therapeutics announce that they have entered into an agreement in which Sistemic will use its miRNA technology platforms to develop an in-process assessment assay for Cynata’s Cymerus™ cell therapy products.
MSCs are currently being explored in nearly 500 clinical trials worldwide, but technologies supporting large-scale manufacturing of MSCs are scare, which is what makes standardization and scale-up of the Cymerus technology important.
To learn more, read the full press release issued by Sistemic Ltd. below. [Read more…]
Gamida Cell Announces $4.4 Million Government Grant to Expand R&D Efforts for NiCord®, CordIn®, and NK Cells
Gamida Cell is an Israeli company specializing in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. Its lead product, NiCord®, offers patients in need of HSCT an alternative to the existing approach of bone marrow transplant by using ex vivo expansion of cord blood. In clinical trials so far, NiCord® has demonstrated rapid engraftment and clinical outcomes that appear comparable to transplantation of peripheral blood.
NiCord®, CordIn™ and other products under development by Gamida Cell, all utilize the company’s proprietary NAM platform technology to expand cells while preserving and enhancing their functionality. [Read more…]
Adult Stem Cell Therapies and the First Inter-American Stem Cell Conference
This is an interview with Ricardo de Cubas, Founder, President, and CEO of Regenestem, LLC. Regenestem is a medical practice company focused on adult stem cell therapies and physician training with particular growth in Latin America.
Regenestem is also presenting an upcoming conference in Cuba devoted to regenerative medicine, in association with the Cuban Institute of Hematology and Immunology. The First Inter American Stem Cell Conference will be held over October 13-15, at the Palacio de Convenciones, in Havana, to explore whether stem cell therapies are ready to become a standard form of treatment. It will also provide hands-on training workshops.
To learn more about progress with adult stem cell therapies and opportunities for education and collaboration in this area, enjoy the interview with Ricardo de Cubas below. [Read more…]
- « Previous Page
- 1
- …
- 291
- 292
- 293
- 294
- 295
- …
- 334
- Next Page »